MX2024006240A - Vacunas contra el metapneumovirus humano. - Google Patents
Vacunas contra el metapneumovirus humano.Info
- Publication number
- MX2024006240A MX2024006240A MX2024006240A MX2024006240A MX2024006240A MX 2024006240 A MX2024006240 A MX 2024006240A MX 2024006240 A MX2024006240 A MX 2024006240A MX 2024006240 A MX2024006240 A MX 2024006240A MX 2024006240 A MX2024006240 A MX 2024006240A
- Authority
- MX
- Mexico
- Prior art keywords
- hmpv
- vaccines
- prefusion
- polypeptides
- human metapneumovirus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000342334 Human metapneumovirus Species 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284405P | 2021-11-30 | 2021-11-30 | |
| PCT/US2022/080555 WO2023102373A1 (en) | 2021-11-30 | 2022-11-29 | Human metapneumovirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006240A true MX2024006240A (es) | 2024-06-11 |
Family
ID=84602059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006240A MX2024006240A (es) | 2021-11-30 | 2022-11-29 | Vacunas contra el metapneumovirus humano. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230310571A1 (https=) |
| EP (1) | EP4440608A1 (https=) |
| JP (1) | JP2024542635A (https=) |
| KR (1) | KR20240118798A (https=) |
| CN (1) | CN118338911A (https=) |
| AR (1) | AR127808A1 (https=) |
| AU (1) | AU2022399571A1 (https=) |
| CA (1) | CA3239417A1 (https=) |
| CO (1) | CO2024007274A2 (https=) |
| IL (1) | IL312997A (https=) |
| MX (1) | MX2024006240A (https=) |
| TW (1) | TW202340227A (https=) |
| WO (1) | WO2023102373A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025119162A1 (zh) * | 2023-12-04 | 2025-06-12 | 深圳深信生物科技有限公司 | 偏肺病毒(mpv)疫苗 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025210592A1 (en) | 2024-04-05 | 2025-10-09 | Sanofi Pasteur Inc. | Muscle cell lnp-mrna quality control assays |
| WO2025250938A2 (en) * | 2024-05-31 | 2025-12-04 | Modernatx, Inc. | Respiratory syncytial virus and metapneumovirus vaccines |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026027730A1 (en) * | 2024-07-31 | 2026-02-05 | Sanofi | Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof |
| CN119978144B (zh) * | 2025-02-14 | 2025-10-17 | 嘉译生物医药(杭州)有限公司 | 一种hMPV病毒融合蛋白F变体、mRNA疫苗及其应用 |
| CN121221752A (zh) * | 2025-02-14 | 2025-12-30 | 北京悦康科创医药科技股份有限公司 | 一种膜融合抑制多肽在抗副黏病毒科病毒感染中的应用 |
| CN119971017B (zh) * | 2025-04-16 | 2025-08-05 | 北京华诺泰生物医药科技有限公司 | 一种hmpv疫苗组合物 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US5684042A (en) | 1997-01-10 | 1997-11-04 | Medlogic Global Corporation | Cyanoacrylate compositions comprising an antimicrobial agent |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| EP2445527A2 (en) * | 2009-06-24 | 2012-05-02 | ID Biomedical Corporation of Quebec | Vaccine |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| EP2519636B8 (en) | 2009-12-28 | 2017-08-09 | DSM IP Assets B.V. | Production of hemagglutinin-neuraminidase protein in microalgae |
| CA3028175C (en) | 2009-12-28 | 2022-05-24 | Sanofi Vaccine Technologies, S.A.S. | Methods of producing heterologous viral neuraminidase proteins in microalgae |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| BR112015022505A2 (pt) | 2013-03-14 | 2017-10-24 | Shire Human Genetic Therapies | avaliação quantitativa para eficiência do cap de rna mensageiro |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| PT4023755T (pt) | 2014-12-12 | 2023-07-05 | CureVac SE | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína |
| ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
| WO2016205691A1 (en) | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| CA3043033A1 (en) | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved ice-based lipid nanoparticle formulation for delivery of mrna |
| AU2017357758B2 (en) | 2016-11-10 | 2023-11-16 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| CA3146675A1 (en) | 2019-07-23 | 2021-01-28 | Translate Bio, Inc. | Stable compositions of mrna-loaded lipid nanoparticles and processes of making |
-
2022
- 2022-11-29 JP JP2024532179A patent/JP2024542635A/ja active Pending
- 2022-11-29 AU AU2022399571A patent/AU2022399571A1/en active Pending
- 2022-11-29 MX MX2024006240A patent/MX2024006240A/es unknown
- 2022-11-29 AR ARP220103276A patent/AR127808A1/es unknown
- 2022-11-29 IL IL312997A patent/IL312997A/en unknown
- 2022-11-29 CA CA3239417A patent/CA3239417A1/en active Pending
- 2022-11-29 CN CN202280078895.3A patent/CN118338911A/zh active Pending
- 2022-11-29 US US18/070,921 patent/US20230310571A1/en active Pending
- 2022-11-29 KR KR1020247021492A patent/KR20240118798A/ko active Pending
- 2022-11-29 EP EP22830106.5A patent/EP4440608A1/en active Pending
- 2022-11-29 WO PCT/US2022/080555 patent/WO2023102373A1/en not_active Ceased
- 2022-11-30 TW TW111145906A patent/TW202340227A/zh unknown
-
2024
- 2024-06-11 CO CONC2024/0007274A patent/CO2024007274A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024007274A2 (es) | 2024-07-18 |
| CN118338911A (zh) | 2024-07-12 |
| US20230310571A1 (en) | 2023-10-05 |
| CA3239417A1 (en) | 2023-06-08 |
| KR20240118798A (ko) | 2024-08-05 |
| EP4440608A1 (en) | 2024-10-09 |
| IL312997A (en) | 2024-07-01 |
| WO2023102373A1 (en) | 2023-06-08 |
| AR127808A1 (es) | 2024-02-28 |
| JP2024542635A (ja) | 2024-11-15 |
| TW202340227A (zh) | 2023-10-16 |
| AU2022399571A1 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006240A (es) | Vacunas contra el metapneumovirus humano. | |
| ZA202501799B (en) | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications | |
| SA518390954B1 (ar) | لقاحات علاجية لفيروس الورم الحليمي البشري 18 | |
| MX2009006755A (es) | Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada. | |
| SG10201909180SA (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| MX2020007675A (es) | Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante. | |
| BR112018001572A2 (pt) | método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo. | |
| WO2020061443A3 (en) | Methods of making and using universal centralized influenza vaccine genes | |
| MY208114A (en) | Hbv vaccines and methods treating hbv | |
| MX2024014468A (es) | Anticuerpos anti-cd63, conjugados y usos de estos | |
| MY195442A (en) | Anti-CD40 Antibodies and Their Uses | |
| MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
| PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
| BR112017014031A2 (pt) | n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado. | |
| MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| MX2022014161A (es) | Vacunas contra sars-cov-2. | |
| PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
| MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
| WO2020070678A3 (en) | Antibodies specific for human and cynomolgus apoc3 and methods of use thereof | |
| MX2024013959A (es) | Proteinas de fusion del hmpv estabilizadas por prefusion | |
| MX2023003934A (es) | Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos. | |
| EP3925968A3 (en) | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell | |
| MX2021013018A (es) | Formulacion de arnm. | |
| BR112021023348A2 (pt) | Vacinação oral à base de levedura | |
| MX2023000881A (es) | Estructura genomica del virus de la influenza. |